Compare Medpace Holdings Inc (MEDP) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Noble Corporation plc — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Noble Corporation plc trades at $44.15 (market cap $7.10B). The key difference: Medpace Holdings Inc is far larger — about 2.4× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.5% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | NE | |
|---|---|---|
Market Cap | $16.90B | $7.10B |
Sector | Technology | Technology |
52-Week High | $620.59 | $54.37 |
52-Week Low | $393.42 | $26.61 |
Enterprise Value | $16.52B | $8.53B |
Dividend Yield | — | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Noble Corporation (NE) trades at $44.08, up 1.22% on the day, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, missing EPS estimates but securing $200 million in new contracts. Revenue and net income are trending lower year-over-year, with a P/E ratio of 47.32 indicating a premium valuation. Recent news highlights multiple law firm investigations into the company.
The outlook is cautious. While a $6.8 billion backlog and consistent dividends provide support, declining profitability, high valuation, and legal scrutiny present significant risks. Analyst consensus is a Hold with a $46.00 price target, suggesting limited near-term upside from current levels amid operational and sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
